Castle Biosciences to Participate in Upcoming Investor Conferences
Castle Biosciences (CSTL) executive management is scheduled to present a company overview at the Stephens Annual Investment Conference on Nov. 18, 2026.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Castle Biosciences (CSTL) executive management is scheduled to present a company overview at the Stephens Annual Investment Conference on Nov. 18, 2026.
The presentation begins at 12:30 p.m. Central time, with a live audio webcast and subsequent replay available on the company's investor website. Castle will also offer one-on-one investor meetings during the Jefferies Global Healthcare Conference, Nov. 16–19, 2026, requested exclusively through Jefferies Financial Group.
AI-generated analysis. How Rhea-AI works. Not financial advice.
A live audio webcast of the Company's presentation will be available by visiting Castle Biosciences' website at ir.castlebiosciences.com/events-presentations/. A replay of the webcast will be available following the conclusion of the live broadcast.
Castle will also be available for one-on-one investor meetings during the Jefferies Global Healthcare Conference, being held Nov. 16-19, 2026. Meetings may be requested exclusively through Jefferies Financial Group.
About Castle Biosciences
Castle Biosciences (Nasdaq: CSTL) is a leading diagnostics company improving health through innovative tests that guide patient care. With a primary focus in dermatologic and gastroenterological disease, we develop personalized, clinically actionable solutions that help improve disease management and patient outcomes.
We put people first—empowering patients and clinicians and informing care decisions through rigorous science and advanced molecular tests that support more confident treatment planning. To learn more, visit www.CastleBiosciences.com and connect with us on LinkedIn, Instagram, Facebook and X.
DecisionDx-Melanoma, DecisionDx-CMSeq, i31-SLNB, i31-ROR, DecisionDx-SCC, MyPath Melanoma, AdvanceAD-Tx, TissueCypher, Esopredict, DecisionDx-UM, DecisionDx-PRAME and DecisionDx-UMSeq are trademarks of Castle Biosciences, Inc.
Investor Contact:
Camilla Zuckero
czuckero@castlebiosciences.com
Media Contact:
Allison Marshall
amarshall@castlebiosciences.com
View original content to download multimedia:https://www.prnewswire.com/news-releases/castle-biosciences-to-participate-in-upcoming-investor-conferences-302921046.html
SOURCE Castle Biosciences, Inc.